Puma Biotechnology, Inc. (PBYI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
10880 Wilshire Boulevard
Los Angeles, CA 90024
United States of America (the)
Phone
424 248 6500
Sector
Healthcare
Industry
Biotechnology
Employees
172
First IPO Date
April 24, 2012
| Name | Title | Pay | Year Born |
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary | 1.98M | 1970 |
| Douglas Hunt FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | 797,757 | 1965 |
| Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer | 904,486 | 1969 |
| Pamela Wilson | Senior Vice President of Clinical Operations | 0 | N/A |
| Roger L. Storms | Senior Vice President of Sales | 0 | N/A |
| Gordon G. Esplin | Chief Accounting Officer | 0 | 1968 |
| Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing | 0 | N/A |
| Heather Blaber | Senior Vice President of Marketing | 0 | N/A |
| Petra Rietschel | Senior Vice President of Clinical Development | 0 | N/A |
| Mariann Ohanesian | Senior Director of Investor Relations | 0 | N/A |
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.